Rejuven Dermaceutical has developed a pipeline around RJV001,  a proprietary mutant collagenase targeting collagen for mild degradation. The most advanced program, RJV001 for injectable fat reduction, has completed the phase I clinical trial in the US. The clinical study results were reported to FDA on 13 May 2022 and approved. The IND approval was received on 30 Dec 2022. Preclinical studies and CMC development were conducted from 2017 to 2019, collaborating with CROs.

Other pipelines, including cancer treatments, are in the patent application stage (PCT state), and preclinical studies are ongoing.